Table 2 Univariable (UVA) and multivariable (MVA) logistic regression model for prediction of treatment recommendation for clinical utility cohort

From: Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy

  UVAMVA
VariableCategoryOR (95% CI)P valueOR (95% CI)P value
Age 1.0 (1.0–1.0)0.5631.0 (0.9–1.0)0.006*
PSA 1.0 (1.0–1.0)0.0651.0 (1.0–1.0)0.519
Pathological GG3 vs 1–22.5 (2.0–3.3)<0.001*2.1 (1.4–2.9)<0.001*
 4–5 vs 1–23.5 (2.7–4.5)<0.001*1.8 (1.2–2.6)0.003*
Pathological T stagepT3a vs pT21.4 (1.1–1.9)0.013*1.3 (0.8–2.0)0.251
 pT3b vs pT22.8 (2.1–3.8)<0.001*1.7 (1.1–2.7)0.030*
SMYes vs no1.2 (1.0–1.5)0.0561.4 (1.0–2.0)0.024*
GC risk groupIntermediate vs low2.5 (1.7–3.8)<0.001*1.9 (1.1–3.3)0.024*
 High vs low9.5 (6.8–13.3)<0.001*8.5 (5.3–13.6)<0.001*
CAPRA-S3–5 vs 0–24.3 (1.5–12.1)0.005*3.9 (1.4–11.2)0.011*
 6–12 vs 0–28.8 (3.2–24.6)<0.001*6.2 (2.1–17.6)<0.001*
GC risk groupIntermediate vs low2.5 (1.7–3.8)<0.001*1.9 (1.1–3.4)0.019*
 High vs low9.5 (6.8–13.3)<0.001*8.7 (5.4–13.8)<0.001*
  1. CAPRA-S Cancer of the Prostate Risk Assessment score, GC genomic classifiers, GG grade group, MVA multivariable analysis, OR odds ratio, PSA prostate-specific antigen, SM surgical margin, UVA univariable analysis, 95% CI 95% confidence interval, *significant p-value